dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
Published 4 years ago • 141 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
1:54
dr. kopetz on the rationale and primary endpoints of the beacon crc study in mcrc
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
1:38
dr. kopetz on the correlation between tumor sidedness and biomarkers in crc
-
1:34
dr. kopetz on the biology of right- versus left-sided crc
-
52:36
inflammation part 1 - how our cells clear pathogens? (phagocytosis)
-
32:43
colorectal cancer and immunotherapy with dr. scott kopetz
-
6:22
erbitux for colon cancer
-
1:14
dr. kopetz on the importance of molecular testing in crc
-
1:39
dr. kopetz on the significance of tumor sidedness in crc
-
2:06
dr. bekaii-saab on the impact of the beacon crc study in braf-mutated crc
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
3:42
evidence in braf-mutant crc tumors
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
7:02
triplet regimens in braf-mutant metastatic crc
-
1:05
dr. nelson on qol data from the beacon crc trial in mcrc
-
2:24
real-world management of patients with braf-v600e mcrc
-
1:32
dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma
-
1:17
dr. long on the rationale for the phase 3 combi-i trial in braf v600–mutant melanoma